Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/52—Purines, e.g. adenine
  • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to the use of GPRI l 9 receptor agonists for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual.
• the present invention further relates to the use of a GPRl 19 receptor agonist 10 in combination with a dipeptidyl peptidase IV (DPP-IV) inhibitor for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual.
• DPP-IV dipeptidyl peptidase IV
• a GPRl 19 receptor agonist and the combination of a GPRl 19 receptor agonist and a DPP-IV inhibitor promote bone formation in an individual.
• Osteoporosis is a disabling disease characterized by the loss of bone mass
• Osteoporosis affects more than 75 million people in Europe, Japan and the United States, and causes more than 2.3 million fractures in Europe and the United States alone. In the United States, osteoporosis affects at least 25% of all postmenopausal white women, and the proportion rises to 70% in women older than 80 years.
• GIP Glucose-dependent Insulinotropic Polypeptide
• Glucose-dependent insulinotropic polypeptide is a peptide incretin hormone of 42 amino acids that is released from duodenal endocrine
• GIP G protein-coupled receptor
• GIP contains an alanine at position 2, it is an excellent substrate for dipeptidyl peptidase-4
• DPP-IV an enzyme regulating the degradation of GEP.
• Full-length GEP(I -42) is rapidly converted to bioinactive GEP(3-42) within minutes of secretion from the gut K cell.
• Inhibition of DPP-IV has been shown to augment GIP bioactivity.
• GIP has been shown to promote bone formation.
• GIP has been shown to activate osteoblastic receptors, resulting in increases in collagen type I synthesis and alkaline phosphatase
• GIP receptor (GEPR) knockout mice evidence a decreased bone size, lower bone mass, altered bone microarchitecture and biochemical properties, and altered parameters for bone turnover, especially in bone formation.
• GPRl 19 is a G protein-coupled receptor (GPRl 19; e.g., human GPRl 19, GenBank ®
• GPRl 19 has been referred to as RUP3 (e.g., International Application No. PCT/US99/23687); GPRl 19 has
• GDER Glucose-Dependent Insu I inotropic Receptor
• Dipeptidyl peptidase IV exhibits catalytic activity against a broad range of peptide substrates that includes peptide hormones, neuropeptides, and chemokines.
• the incretins glucagon-like peptide 1 (GLP-I) and glucose-dependent insulinotropic polypeptide (GEP), 5 which stimulate glucose-dependent insulin secretion and otherwise promote blood glucose homeostasis, are rapidly cleaved by DPP-IV at the position 2 alanine leading to inactivation of their biological activity. Both pharmacological and genetic attenuation of DPP-FV activity are associated with enhanced incretin action *>t vivo.
• a second-generation DPP-FV inhibitor, LAF237 (vildagliptin) (Ahren et al., J Clin Endocrinol Metab (2004) 89:2078-20S4; and Villhauer et al., J Med Chem (2003)
• the present invention relates to the unexpected discovery by Applicant that administration of a GPRI 19 agonist, such as by oral administration, can act at GPRl 19 receptor to increase a GFP level in an individual.
• a GPRl 19 agonist in combination with a dipeptidyl peptidase IV (DPP-IV) inhibitor can provide an effect in increasing a GFP level in an individual over that provided by the DPP-FV inhibitor alone.
• DPP-IV dipeptidyl peptidase IV
• the present invention concerns a GPRl 19 agonist as
• the present invention further concerns the use of a GPRl 19 agonist and the use of the combination of a GPRl 19 agonist with a DPP-FV inhibitor for treating or preventing a condition characterized by low bone
• a GPRl 19 agonist alone or in combination with a DPP-IV inhibitor is useful for promoting (e.g., increasing) bone formation in an individual.
• the individual is a human.
• the present invention features a method of treating or preventing a condition characterized by low bone mass comprising administering to an individual in need thereof a therapeutically effective amount of a composition comprising a GPR l 19 agonist.
• the present invention additionally features a method of treating or preventing a condition characterized by low 5 bone mass comprising administering to an individual in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a GPRl 19 agonist and a pharmaceutically acceptable carrier.
• the condition characterized by low bone mass is selected from the group consisting of osteopenia, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, Paget's disease,
• the condition characterized by low bone mass is osteoporosis.
• osteoporosis is primary osteoporosis.
• osteoporosis is secondary osteoporosis.
• the present invention features a method of increasing bone mass comprising administering to
• the present invention additionally features a method of increasing bone mass comprising administering to an individual in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a GPRl 19 agonist and a pharmaceutically acceptable carrier.
• the individual in need of increased bone mass has a bone mineral density
• the individual in need of increased bone mass is in need of treatment of bone fracture.
• the individual has a traumatic bone fracture, a long-term bone fracture, or an osteoporotic fracture.
• the individual in need of increased bone mass is in
• the bone disease is selected from the group consisting of osteopenia, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, Paget's disease, bone loss due to metastatic cancer, osteolytic lesions, curvature of the spine, and loss of height.
• the bone disease is osteoporosis.
• osteoporosis is primary
• osteoporosis is secondary osteoporosis.
• the individual in need of increased bone mass is in need of enhanced bone healing following facial reconstruction, maxillary reconstruction, mandibular reconstruction, periodontal disease or tooth extraction, enhanced long bone extension, enhanced prosthetic ingrowth or increased bone synostosis.
• the GPRl 19 agonist is a selective GPRl 19 agonist. In certain embodiments, the GPRl 19 agonist is selected from the left column of Table D. In certain embodiments, the administering is oral.
• the GPRl 19 agonist is administered in an amount sufficient to increase a GIP level in the individual.
• the GIP level is a blood or plasma total GIP level.
• the GIP level is a blood or plasma bioactive GIP level.
• the individual is a vertebrate. In certain embodiments, the individual 5 is a mammal. In certain embodiments, the individual is a human.
• the administering is carried out in a single dose.
• the individual is not a human and the administering is carried out in a single dose.
• the administering is carried out in multiple doses over a period of 10 greater than 24 days, greater than 36 days, greater than 48 days or greater than 60 days. In certain embodiments, the multiple doses are consecutive daily doses. In certain embodiments, the individual is not a human and the administering is carried out in multiple doses over a period of greater than 24 days, greater than 36 days, greater than 48 days or great than 60 days. In certain embodiments, the individual is not a human and the multiple doses are consecutive daily doses.
• the individual is a human and the administering is carried out in a single dose.
• the individual is a human and the administering is carried out in consecutive daily doses over a period of at least 2 days, at least 7 days, at least 14 days, at least 30 days or at least 60 days.
• the individual is a human and the administering is carried out in multiple doses over a period of greater than 8 weeks, greater than 12 weeks, greater than 16 weeks, greater than 20 weeks, greater than 24 weeks, greater than 28 weeks, greater than 32 weeks or greater than 36 weeks.
• the multiple doses are consecutive daily doses.
• the present invention features use of a GPRl 19 agonist to treat a condition
• the human or animal body is a human body.
• the condition characterized by low bone mass is selected from the group consisting of osteopenia, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, Paget's disease, bone loss due to metastatic cancer, osteolytic lesions, curvature of the spine, and
• the condition characterized by low bone mass is osteoporosis.
• osteoporosis is primary osteoporosis. In certain embodiments, osteoporosis is secondary osteoporosis.
• the present invention features use of a GPR l 19 agonist to increase bone mass in the human or animal body by therapy.
• the human or animal body is a human body.
• the human or animal body has a bone mineral density (BMD) greater than 1 (T- score ⁇ -I ) or greater than or equal to 1.5 (T-score ⁇ -1.5), 2 (T-score ⁇ -2) or 2.5 (T-score ⁇ -2.5) standard deviations below the young adult reference mean.
• BMD bone mineral density
• the human or animal body is in need of treatment of bone fracture.
• the human or animal body has a traumatic bone fracture, a long-term bone fracture, or an osteoporotic fracture.
• the human or animal body is in need of treatment of a bone disease.
• the bone disease is selected from the group consisting of osteopenia, osteoporosis, 5 rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, Paget' s disease, bone loss due to metastatic cancer, osteolytic lesions, curvature of the spine, and loss of height.
• the bone disease is osteoporosis.
• osteoporosis is primary osteoporosis.
• osteoporosis is secondary osteoporosis.
• the human or animal body is in need of enhanced
• the GPRl 19 agonist is a selective GPRl 19 agonist. In certain embodiments, the GPRl 19 agonist is selected from the left column of Table D.
• the GPRl 19 agonist is provided in an amount sufficient to increase a
• the GIP level in the human or animal body is a blood or plasma total GIP level.
• the GD? level is a blood or plasma bioactive GIP level.
• the human or animal body is a human body.
• the present invention features use of a GPRl 19 agonist for the manufacture
• the condition characterized by low bone mass is selected from the group consisting of osteopenia, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, Paget's disease, bone loss due to metastatic cancer, osteolytic lesions, curvature of the spine, and loss of height.
• the condition characterized by low bone mass is selected from the group consisting of osteopenia, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, Paget's disease, bone loss due to metastatic cancer, osteolytic lesions, curvature of the spine, and loss of height.
• the condition characterized by low bone mass is osteoporosis.
• osteoporosis is primary osteoporosis.
• osteoporosis is secondary osteoporosis.
• the present invention features use of a GPRl 19 agonist for the manufacture of a medicament for increasing bone mass in an individual.
• the individual has a bone mineral
• the individual is in need of treatment of bone fracture.
• the individual has a traumatic bone fracture, a long-term bone fracture, or an osteoporotic fracture.
• the individual is in need of treatment of a bone disease.
• the bone disease is selected from the group consisting of osteopenia, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, Paget's disease, bone loss due to metastatic cancer, osteolytic lesions,
• the bone disease is osteoporosis.
• osteoporosis is primary osteoporosis.
• osteoporosis is secondary osteoporosis.
• the individual is in need of enhanced bone healing following facial reconstruction, maxillary reconstruction, mandibular reconstruction, periodontal 5 disease or tooth extraction, enhanced long bone extension, enhanced prosthetic ingrowth or increased bone synostosis.
• the GPRl 19 agonist is a selective GPRl 19 agonist. In certain embodiments, the GPR l 19 agonist is selected from the left column of Table D.
• the GPRl 19 agonist is provided in an amount sufficient to increase a
• the GIP level is a blood or plasma total GEP level. In certain embodiments, the GIP level is a blood or plasma bioactive GIP level.
• the individual is a vertebrate. In certain embodiments, the individual is a mammal. In certain embodiments, the individual is a human.
• the present invention features a method of treating or preventing a
• condition characterized by low bone mass comprising administering to an individual in need thereof a therapeutically effective amount of a composition comprising a GPRl 19 agonist and a DPP-IV inhibitor.
• the present invention additionally features a method of treating or preventing a condition characterized by low bone mass comprising administering to an individual in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a GPRl 19 agonist and a
• the condition characterized by low bone mass is selected from the group consisting of osteopenia, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, Paget's disease, bone loss due to metastatic cancer, osteolytic lesions, curvature of the spine, and loss of height.
• the condition characterized by low bone mass is selected from the group consisting of osteopenia, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, Paget's disease, bone loss due to metastatic cancer, osteolytic lesions, curvature of the spine, and loss of height.
• the condition characterized by low bone mass is selected from the group consisting of osteopenia, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteoto
• bone mass is osteoporosis.
• osteoporosis is primary osteoporosis.
• osteoporosis is secondary osteoporosis.
• the present invention features a method of increasing bone mass comprising administering to an individual in need thereof a therapeutically effective amount of a composition comprising a GPRl 19 agonist and a DPP-IV inhibitor.
• the present invention additionally features a method of
• the individual in need of increased bone mass is in need of treatment of bone fracture.
• the individual has a traumatic bone fracture, a long-term bone fracture, or an osteoporotic fracture.
• the individual in need of increased bone mass is in need of treatment of bone fracture.
• the individual has a traumatic bone fracture, a long-term bone fracture, or an osteoporotic fracture.
• the individual in need of increased bone mass is in need of treatment of bone fracture.
• the individual has a traumatic bone fracture, a long-term bone fracture, or an osteoporotic fracture.
• the bone disease is selected from the group consisting of osteopenia, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, Paget's disease, bone loss due to metastatic cancer, osteolytic lesions, 5 curvature of the spine, and loss of height.
• the bone disease is osteoporosis.
• osteoporosis is primary osteoporosis.
• osteoporosis is secondary osteoporosis.
• the individual in need of increased bone mass is in need of enhanced bone healing following facial reconstruction, maxillary reconstruction, mandibular reconstruction, periodontal disease or tooth extraction, enhanced long bone extension, 10 enhanced prosthetic ingrowth or increased bone synostosis.
• the GPRI 19 agonist is a selective GPRl 19 agonist. In certain embodiments, the GPRl 19 agonist is selected from the left column of Table D.
• the DPP-IV inhibitor is a selective DPP-FV inhibitor. In certain embodiments, the DPP-FV inhibitor is selected from the right column of Table D.
• the GPR 1 19 agonist is selected from the left column of Table D and the DPP-FV inhibitor is selected from the right column of Table D.
• the administering is oral.
• the GPRl 19 agonist or the combination of the GPRl 19 agonist and the DPP-IV inhibitor is administered in an amount sufficient to increase a GIP level in the individual.
• the GIP level is a blood or plasma total GIP level.
• the GD? level is a blood or plasma bioactive GD? level.
• the individual is a vertebrate. In certain embodiments, the individual is a mammal. In certain embodiments, the individual is a human.
• the administering is carried out in a single dose.
• the individual is not a human and the administering is carried out in a single dose.
• the administering is carried out in multiple doses over a period of greater than 24 days, greater than 36 days, greater than 48 days or greater than 60 days. In certain embodiments, the multiple doses are consecutive daily doses . In certain embodiments, the individual 30 is not a human and the administering is carried out in multiple doses over a period of greater than 24 days, greater than 36 days, greater than 48 days or great than 60 days. In certain embodiments, the individual is not a human and the multiple doses are consecutive daily doses.
• the individual is a human and the administering is carried out in a single dose.
• the individual is a human and the administering is carried out in consecutive daily doses over a period of at least 2 days, at least 7 days, at least 14 days, at least 30 days or at least 60 days.
• the individual is a human and the administering is carried out in multiple doses over a period of greater than 8 weeks, greater than 12 weeks, greater than 16 weeks, greater than 20 weeks, greater than 24 weeks, greater than 28 weeks, greater than 32 weeks or greater than 36 weeks.
• the present invention features use of a GPRl 19 agonist in combination with a DPP-IV inhibitor to treat a condition characterized by low bone mass in the human or animal body by therapy.
• the human or animal body is a human body.
• the condition characterized by low bone mass is selected from the group consisting of osteopenia, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss,
• osteotomy bone loss childhood idiopathic bone loss, Paget's disease, bone loss due to metastatic cancer, osteolytic lesions, curvature of the spine, and loss of height.
• the condition characterized by low bone mass is osteoporosis.
• osteoporosis is primary osteoporosis.
• osteoporosis is secondary osteoporosis.
• the present invention features use of a GPRl 19 agonist in combination with a DPP-FV
• the human or animal body is a human body.
• the human or animal body has a bone mineral density (BMD) greater than 1 (T-score ⁇ -1 ) or greater than or equal to 1.5 (T-score ⁇ - 1.5), 2 (T-score ⁇ -2) or 2.5 (T-score ⁇ -2.5) standard deviations below the young adult reference mean.
• BMD bone mineral density
• the human or animal body is in need of treatment of bone fracture.
• the human or animal body has a traumatic bone fracture, a long-term bone fracture, or an osteoporotic fracture.
• the human or animal body is in need of treatment of a bone disease.
• the bone disease is selected from the group consisting of osteopenia, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, Paget's disease, bone loss
• the bone disease is osteoporosis.
• osteoporosis is primary osteoporosis.
• osteoporosis is secondary osteoporosis.
• the human or animal body is in need of enhanced bone healing following facial reconstruction, maxillary reconstruction, mandibular reconstruction, periodontal disease or tooth
• the GPRl 19 agonist is a selective GPRl 19 agonist. In certain embodiments, the GPR l 19 agonist is selected from the left column of Table D.
• the DPP-FV inhibitor is a selective DPP-FV inhibitor.
• the DPP-FV inhbitor is selected from the right column of Table D.
• the GPRl 19 agonist is selected from the left column of Table D and the DPP- TV inhibitor is selected from the right column of Table D.
• the GPR] 19 agonist or the combination of a GPRl 19 agonist and the DPP-W inhibitor is provided in an amount sufficient to increase a GIP level in the human or animal body.
• the GIP level is a blood or plasma total G EP level.
• the GDP level is a blood or plasma bioactive GIP level. 5
• the human or animal body is a human body.
• the present invention features use of a GPRl 19 agonist in combination with a DPP-IV inhibitor for the manufacture of a medicament for the treatment or prevention of a condition characterized by low bone mass in an individual.
• the condition characterized by low bone mass is selected from the group consisting of osteopenia, osteoporosis, rheumatoid
• the condition characterized by low bone mass is osteoporosis.
• osteoporosis is primary osteoporosis.
• osteoporosis is secondary osteoporosis.
• the present invention features use of a GPRl 19 agonist in combination with a DPP-FV inhibitor for the manufacture of a medicament for increasing bone mass in an individual.
• the individual has a bone mineral density (BMD) greater than 1 (T-score ⁇ -J ) or greater than or equal to 1.5 (T-score ⁇ -1 .5), 2 (T-score ⁇ -2) or 2.5 (T-score ⁇ -2.5) standard deviations below the young adult reference mean.
• BMD bone mineral density
• the individual has a traumatic bone fracture, a long-term bone fracture, or an osteoporotic fracture.
• the individual is in need of treatment of a bone disease.
• the bone disease is selected from the group consisting of osteopenia, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, Paget's disease, bone loss
• the bone disease is osteoporosis.
• osteoporosis is primary osteoporosis.
• osteoporosis is secondary osteoporosis.
• the individual is in need of enhanced bone healing following facial reconstruction, maxillary reconstruction, mandibular reconstruction, periodontal disease or tooth extraction, enhanced
• the GPRl 19 agonist is a selective GPRI 19 agonist. In certain embodiments, the GPRl 19 agonist is selected from the left column of Table D.
• the DPP-IV inhibitor is a selective DPP-IV inhibitor.
• the DPP-FV inhbitor is selected from the right column of Table D.
• the GPRl 19 agonist is selected from the left column of Table D and the DPP-FV inhibitor is selected from the right column of Table D.
• the GPRl 19 agonist or the combination of the GPRl 29 agonist and the DPP-IV inhibitor is provided in an amount sufficient to increase a GIP level in the individual.
• the GIP level is a blood or plasma total GIP level.
• the GIP level is a blood or plasma bioactive GEP level.
• the individual is a vertebrate. In certain embodiments, the individual is a mammal. In certain embodiments, the individual is a human.
• the invention features a method according to the first aspect or to the fourth aspect, optionally further comprising the step of identifying the individual as an individual judged by a caregiver to require or benefit from said treating or preventing a condition characterized 10 by low bone mass or from said increasing bone mass, and optionally further comprising the step of identifying achievement of therapeutic efficacy of said administering of said composition or said pharmaceutical composition.
• the invention features a method of the first aspect, further comprising the step of identifying the individual as an individual judged by a caregiver to require or benefit from 15 said treating or preventing a condition characterized by low bone mass or from said increasing bone mass.
• the invention features a method of the fourth aspect, further comprising the step of identifying the individual as an individual judged by a caregiver to require or benefit from said treating or preventing a condition characterized by low bone mass or from said 20 increasing bone mass.
• the invention features a method of the first aspect, further comprising the step of identifying achievement of therapeutic efficacy of said administering of said composition or said pharmaceutical composition.
• the invention features a method of the fourth aspect, further 25 comprising the step of identifying achievement of therapeutic efficacy of said administering of said composition or said pharmaceutical composition.
• the invention features a method of the first aspect, further comprising the step of of identifying the individual as an individual judged by a caregiver to require or benefit from said treating or preventing a condition characterized by low bone mass or from said increasing
• the invention features a method of the fourth aspect, further comprising the step of of identifying the individual as an individual judged by a caregiver to require or benefit from said treating or preventing a condition characterized by low bone mass or from said
• the caregiver is a physician, a nurse or a nurse practioner.
• the caregiver is a veterinarian.
• administering comprises measuring a level of bone mass in the individual.
• said measuring a level of bone mass comprises measuring the level of bone mass using dual energy X- ray absorptiometry (DXA).
• said measuring a level of bone mass using DXA comprises measuring a T-score using DXA.
• said measuring a T-score using DXA comprises measuring a T-score using DXA.
• DXA comprises measuring a T-score at the hip using DXA. It is expressly contemplated that said
• measuring a level of bone mass may comprise measuring a level of bone mass using a technique other than DXA, such as single X-ray absorbtiometry (SXA) [see, e.g., World Health Organization
• said identifying achievement of therapeutic efficacy of said administering comprises measuring a GDP level in the individual.
• the GIP 15 level is a blood or plasma total GIP level.
• the GD? level is a blood or plasma bioactive GIP level.
• FIG. 1 shows a pharmacodynamic analysis of an effect of administration of GPR l 19 agonist on blood GIP level in wild-type mice.
• A. A time course analysis carried out using Compound IZ as the GPRl 19 agonist.
• B. A time course analysis carried out using Compound 3Z as the GPRl 19 agonist.
• C. A dose titration analysis carried out using Compound 3Z as the GPRl 19 agonist.
• FIG. 2 shows an effect of administration of GPRl 19 agonist on blood GIP level in GPRl 19- 25 deficient (knockout) mice compared to wild-type mice.
• FIG. 3 shows an effect of administration of a DPP-IV inhibitor in combination with a GPRl 19 agonist compared with the DPP-IV inhibitor alone on blood GD? level in wild-type mice.
• 30 Compound IZ was used as the GPRl 19 agonist.
• AR247810 was used as the DPP-IV inhibitor.
• This invention is concerned with certain compounds, or pharmaceutically acceptable salts thereof, for the treatment or prevention in an individual of a condition characterized by low bone
• This invention is further concerned with certain compounds, or pharmaceutically acceptable salts thereof, for increasing bone mass in an individual.
• Applicant has found that administering of a GPRI 19 agonist to an individual, such as by oral administration, can
• a GPRl 19 agonist is useful for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual.
• This invention is concerned with the combination of certain compounds, or pharmaceutically 5 acceptable salts thereof, for the treatment or prevention in an individual of a condition characterized by low bone mass, such as osteoporosis.
• This invention is further concerned with the combination of certain compounds, or pharmaceutically acceptable salts thereof, for increasing bone mass in an individual.
• An amount of a GPR l 19 agonist in combination with an amount of a DPP-IV inhibitor can provide an effect in increasing a GIP level in an individual over that provided by the amount of
• the GPR l 19 agonist or the amount of the DPP-P/ inhibitor alone is useful for the treatment or prevention in an individual of a condition characterized by low bone mass, such as osteoporosis.
• the combination of a GPRl 19 agonist and a DPP-IV inhibitor is useful for increasing bone mass in an individual.
• the present invention it is possible to treat or prevent a condition characterized by low bone mass more effectively than by use of a GPRl 19 agonist or a DPP-IV inhibitor alone, thereby reducing the likelihood of unwanted side-effects associated with inhibition of DPP-IV activity.
• a combination of a GPRl 19 agonist and a DPP-IV inhibitor in accordance with the present invention it is possible to increase bone mass more effectively than by use of a GPRI 19 agonist or a DPP-FV
• the present invention provides new, unexpected and advantageous approaches to treating or preventing a condition characterized by low bone mass, such as osteoporosis, and to increasing bone mass in an individual.
• the present invention additionally provides new, unexpected and advantageous approaches to increasing a GIP level in an individual.
• ligand shall mean a molecule (e.g., test compound) that specifically binds to a polypeptide, such as GPRI 19 or DPP-P/.
• a ligand may be, for example, a polypeptide, a lipid, a small molecule, an antibody.
• Compound IZ is an exemplary ligand of
• Compound 35 is an exemplary ligand of GPRl 19 receptor polypeptide.
• Compound 2Z is identical to a compound disclosed in International Patent Application No. PCT/US2004/022417 (published as WO 2005/007658).
• Compound 3Z is an exemplary ligand of GPRl 19 receptor polypeptide.
• An endogenous ligand is a ligand that is an endogenous, natural ligand for a native polypeptide, such as GPR l 19 or DPP-P/.
• a ligand may be an "antagonist”, “agonist”, “partial agonist”, or “inverse agonist", or the like.
• a ligand may be an "inhibitor.”
• agonist shall mean an agent (e.g., ligand) that by virtue of binding to a GPCR activates the GPCR so as to elicit an intracellular response mediated by the GPCR.
• partial agonist shall mean an agent (e.g., ligand) that by virtue of 10 binding to a GPCR activates the GPCR so as to elicit an intracellular response mediated by the GPCR, albeit to a lesser exent or degree than does a full agonist.
• antagonist shall mean an agent (e.g., ligand) that binds, and in particular embodiment binds competitively, to a GPCR at about the same site as an agonist or partial agonist but which does not activate an intracellular response initiated by the active form of the GPCR, and can
• An anatagonist typically does not diminish the baseline intracellular response in the absence of an agonist or partial agonist.
• inverse agonist shall mean an agent (e.g., ligand) which binds to a GPCR and which inhibits the baseline intracellular response initiated by the active form of the receptor below the normal base level activity which is observed in the absence of an agonist or partial agonist.
• GPRl 19 agonist refers to a compound that binds to GPRl 19 receptor and acts as an agonist.
• Compound IZ is an exemplary GPRl 19 agonist (see, Table E, which sets forth the chemical structure and chemical name of Compound IZ).
• Compound I Z is identical to a compound disclosed in International Patent Application No. PCT/US2004/001267 (published as
• (2-Fluoro-4-methanesulfonyl-phenyl)- ⁇ 6-[4-(3-isopropyl-[l ,2,4]oxadiazol-5-y!- piperidin-l -yl]-5-nitro-pyrimidin-4-yl ⁇ -amine is an exemplary GPR] J 9 agonist.
• Compound 2Z is an exemplary GPRl 19 agonist.
• Compound 2Z is identical to a compound disclosed in International Patent Application No. PdYUS2004/022417 (published as WO 2005/007658).
• Compound 3Z is an 5 exemplar)' GPRl 19 agonist.
• Compound 3Z is identical to a compound disclosed in International Patent Application No. PCT/US2004/022327 (published as WO 2005/007647).
• selective GPRl 19 agonist refers to a GPRl 19 agonist having selectivity for GPRl 19 receptor over one or more related receptors, such as corticotrophin-releasing factor- 1 (CRF-I ) receptor.
• Compound IZ is an exemplary selective GPRl 19 agonist (see, Table E,
• Compound IZ is identical to a compound disclosed in International Patent Application No. PCT/US2004/001267 (published as WO 2004/065380).
• (2-F ⁇ uoro-4-methanesulfonyl-phenyl)- ⁇ 6-[4-(3-isopropyl- [l ,2,4]oxadiazol-5-yl)-pipe ⁇ din-l -yl]-5-nitro-pyrimidin-4-yl ⁇ -amine is an exemplary selective GPR l 19 agonist.
• Compound 2Z is an exemplary selective GPR l 19 agonist.
• Compound 2Z is
• Compound 3Z is an exemplary selective GPRl 19 agonist.
• Compound 3Z is identical to a compound disclosed in International Patent Application No. PCT/US2004/022327 (published as WO 2005/007647).
• DPP-IV inhibitor refers to a compound that binds to DPP-IV and
• AR247810 is an exemplary DPP-IV inhibitor.
• selective DPP-IV inhibitor refers to a DPP-IV inhibitor having selectivity for DPP-IV over related peptidases, such as one or more of post-proline-cleaving enzyme (PPCE), dipeptidyl peptidase II (DPP-II), dipeptidyl peptidase 8 (DPP-8), and dipeptidyl peptidase 9 (DPP-9).
• PPCE post-proline-cleaving enzyme
• DPP-II dipeptidyl peptidase II
• DPP-8 dipeptidyl peptidase 8
• DPP-9 dipeptidyl peptidase 9
• blood GIP level shall mean blood GIP concentration.
• a blood GIP concentration in certain embodiments, a blood GIP concentration.
• a blood GIP level is a blood total GIP level.
• a blood GIP level is a blood biologically active (bioactive) GIP level.
• bioactive GIP is GEP having agonist activity at GEPR.
• a blood GIP level is a plasma GEP level.
• the term "individual,” as used herein, refers to a vertebrate, including but not limited to fish
• the individual is a fish. In certain embodiments, the individual is an amphibian.
• the individual is a reptile. In certain embodiments, the individual is a bird. In certain embodiments, the individual is a turkey. Over the past 25 yr, commercial selection pressure for turkeys with larger breast muscle mass has placed increasing demands on skeletal integrity. The
• the individual is a mammal.
• the 5 individual is a mouse, a rat, a hamster, a rabbit, a pig, a dog, a cat, a horse, a cow, a sheep, a goat, a non-human primate or a human (which may be included in embodiments of the invention individually or in any combination).
• the individual is a horse. Performance horses, which are horses involved in activities such as racing, pacing and other competitive events, are susceptible to bone fracture.
• the individual is a dog or a cat.
• the individual is a mammal.
• the 5 individual is a mouse, a rat, a hamster, a rabbit, a pig, a dog, a cat, a horse, a cow, a sheep, a goat, a non-human primate or a human (which may be included in embodiments of the invention individually or in any combination).
• the individual is a horse. Performance horses, which are horses involved in activities such as racing
• the 10 individual is a human companion animal (such as a dog, a cat, etc.), a farm animal (such as a cow, a sheep, a goat, a pig, a chicken, etc.), a sports animal (such as a horse, a dog, etc ⁇ , a beast of burden (such as a mule, a camel, etc.) or an exotic animal (such as an animal found in a zoo, etc.), which may be included in embodiments of the invention individually or in any combination.
• the individual is a non-human mammal.
• the individual is a
• non-human primate such as a rhesus monkey, a chimpanzee, etc.
• the individual is a human.
• in need of prevention or treatment refers to a judgement made by a caregiver (e.g. physician, nurse, nurse practitioner in the case of humans; veterinarian in the case of non-human vertebrates, and in particular embodiment non-human mammals) that an individual
• terapéuticaally effective amount refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes one or more of the following:
• Preventing the disease for example, preventing a disease, condition or disorder in an individual that may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease,
• Inhibiting the disease for example, inhibiting a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or
• Ameliorating the disease for example, ameliorating a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).
• therapeutic efficacy refers to elicitation of the biological or medicinal 35 response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes one or more of the following:
• Preventing the disease for example, preventing a disease, condition or disorder in an individual that may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease,
• Inhibiting the disease for example, inhibiting a disease, condition or disorder in an individual 5 that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology), and
• Ameliorating the disease for example, ameliorating a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).
• amount that is effective to prevent refers to that amount of drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented. In many instances, the amount that is effective to prevent is the same as the therapeutically effective amount.
• composition shall mean a material comprising at least one component.
• active ingredient shall mean any component that provides pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease.
• composition shall mean a composition comprising at least one active ingredient, whereby the composition is amenable to investigation and treatment in a mammal.
• pharmaceutically acceptable it is meant that the carrier, vehicle, diluent, excipients, 20 and/or salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.
• drug form shall mean the physical form in which a drug is produced and dispensed, such as a tablet, capsule, or an injectable.
• bone is intended the dense, semi-rigid, porous, calcified connective tissue forming the 25 major portion of the skeleton of most vertebrates, comprising a dense organic matrix and an inorganic, mineral component. Bone is any of numerous anatomically distinct structures making up the skeleton of a vertebrate.
• BMD bone mineral density
• BMD in humans is usually measured by a standard radiographic technique, dual energy X-ray 30 absorptiometry (DXA).
• DXA is the most highly developed technically and the most thoroughly validated biologically.
• DXA technology with suitably adapted software, can also be used to reliably assess BMD in animal studies.
• DXA is used in the diagnosis of osteoporosis, prognosis (fracture prediction), monitoring the natural history of the disorder, and assessing response to treatment.
• low bone mass refers to any decrease or reduction in bone mineral density (BMD) in an individual, and includes both osteoporosis and osteopenia as defined in proposals by the World Health Organization (WHO).
• the WHO has defined normal as a value of
• the WHO has defined osteopenia as a value of BMD more than 1 standard deviation below the young adult mean, but less than 2.5 standard deviations below this value (T-score ⁇ -1 and > -2.5).
• the WHO has characterized osteoporosis as a more severe form of osteopenia, and has defined it by value of BMD 5 2.5 standard deviations or more blow the young adult mean (T-score ⁇ -2.5). (See, e.g...
• osteopenia is defined as a T-score of less than -1 and greater than -2
• osteoporosis is defined as a T-score of less than or equal to -2.
• the T-score is measured at the
• osteoporosis as used herein is defined by a value of BMD 2 standard deviations or more below the young adult reference mean (T-score ⁇ -2) or refers to a diagnosis made by a caregiver (e.g. physician, nurse, nurse practitioner in the case of humans; veterinarian in the case of non-human vertebrates).
• a caregiver e.g. physician, nurse, nurse practitioner in the case of humans; veterinarian in the case of non-human vertebrates.
• Osteoporosis can be classified as either primary or secondary. (See, e.g., World Health
• osteoporosis encompasses primary osteoporosis and secondary osteoporosis.
• osteoporosis is primary osteoporosis.
• osteoporosis is secondary osteoporosis.
• Primary osteoporosis is associated with menopause (natural, premature, or surgical), aging, or both. It shall be understood that in the present invention, primary osteoporosis associated with menopause (natural, premature, or surgical), primary osteoporosis associated with aging, and primary osteoporosis associated with menopause and aging can be included in embodiments individually or in any combination.
• Bone osteoporosis refers to osteoporosis which is associated not with menopause or aging but rather with medical conditions or with the use of medications or drugs.
• An increased risk of osteoporosis is associated with a host of medical conditions, including but not limited to endocrine and metabolic disorders, and malignant disease, and with the use of certain medications and drugs, examples of which are well known to those skilled in the art (see, e.g., World
• Secondary osteoporosis can also be associated with immobilization.
• a diagnosis of osteoporosis secondary to a medical condition, to use of a medication or drug, or to immobilization can be made by a caregiver (e.g. physician, nurse, nurse practitioner in
• bone fracture is intended a complete or incomplete break, rupture or crack of a bone. Diagnosis of fractures normally depends upon clinical examination and radiological findings.
• bone fractures include, but are not limited to, traumatic fractures, long-term fractures, and pathological fractures.
• Traumatic fracture shall refer to an immediate fracture which involves a supraliminal trauma with a degree of local violence that exceeds the natural elasticity of the bone. It 5 can be accompanied by simultaneous injury to the soft tissues and very often the skin. A traumatic fracture can be closed (the adjacent soft tissue can be injured but the covering soft parts are largely preserved). A traumatic fracture can be open (the broken ends of the bone are freed by extensive soft tissue injury so that pathogens from outside can enter the wound directly).
• Long-term fracture as used herein shall refer to a chronic fracture, fatigue fracture, stress
• Pathological fracture shall refer to a spontaneous fracture type II.
• a pathological fracture arises spontaneously, without adequate trauma to account for it.
• the bone may have been previously damaged, either by a systemic disease (e.g., osteoporosis, osteodystrophy, or Paget' s osteitis deformans) or by a local bone lesion (e.g., metastasis, radioosteonecrosis, or bone
• Fractures also include, but are not limited no, oblique torsion fracture, transverse fracture, comminuted fracture, compression fracture, rib fractures, creeping fracture, and fractured femoral neck (Adler, Claus-Peter, BONE DISEASES, Springer-Verlag, Germany (2000)).
• condition characterized by low bone mass includes but is not
• secondary osteoporosis is associated with a medical condition.
• secondary osteoporosis is associated with use of a medication or drug.
• secondary osteoporosis is
• Conditions characterized by low bone mass include but are not limited to Paget's disease, bone loss due to metastatic cancer, and osteolytic lesions such as those caused by neoplastic disease, radiotherapy, or chemotherapy. Conditions characterized by low bone mass also include but are not limited to long-term complications of osteoporosis such as curvature of the spine, loss of height and prosthetic surgery. It shall be understood that in the present invention,
• bone disease refers to a disorder or condition relating to abnormality of the bone. Bone diseases that can be treated according to the invention, by increasing bone mass or bone
• osteopenia include osteoporosis, primary osteoporosis, secondary osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, alveolar bone loss, osteotomy bone loss, childhood idiopathic bone loss, curvature of the spine, and loss of height.
• secondary osteoporosis is associated with a medical conditions.
• secondary osteoporosis is associated with the use of a medication or drug.
• secondary osteoporosis is associated with immobilization.
• Bone diseases that can be treated according to the invention, by increasing bone mass or bone growth also include but are not limited to Paget's disease and bone loss due to metastatic cancer.
• Destructive bone disorders that can be treated according to the invention, by increasing bone mass or growth, include but are not limited
• osteoporosis 10 to osteoporosis, osteoarthritis, and osteolytic lesions such as those caused by neoplastic disease, radiotherapy, or chemotherapy.
• bone diseases that can be treated according to the invention, by increasing bone mass or growth, can be included in embodiments individually or in any combination.
• the present invention also relates to the other conditions that derive benefit from treatment according to the invention, by increasing bone mass or bone growth, including but not limited to
• C ⁇ .s acyl denotes a C 1 . 5 alkyl radical attached to a carbonyl wherein the definition
• alkyl 25 of alkyl has the same definition as described herein; some examples include but not limited to, acetyl, propionyl, n-butanoyl, /.y ⁇ -butanoyl, sec-butanoyl, t-butanoyl (i.e., pivaloyl), pentanoyl and the like.
• C 1 . 5 acyloxy denotes an acyl radical attached to an oxygen atom wherein acyl has the same definition has described herein; some examples include but not limited to acetyloxy, propionyloxy, butanoyloxy, /s ⁇ -butanoyloxy, sec-butanoyloxy, t-butanoyloxy and the like,
• Ci. ⁇ acylsulfonamide refers to a Q -6 acyl attached directly to the nitrogen of the sulfonamide, wherein the definitions for C
• Some embodiments of the present invention are when acylsulfonamide is a C ⁇ .$ acylsulfonamide, some 35 embodiments are C, . 4 acylsulfonamide, some embodiments are C1.3 acylsulfonamide, and some
• - 20 - embodiments are C,. 2 acylsulfonamide.
• butyrylsulfamoyl 2-methyl-butyrylsulfamoyl, 3-methyl-butyrylsulfamoyl, 2,2-dimethyl- propionylsulfamoyl, pentanoylsulfamoyl, 2-methyl-pentanoylsulfamoyl, 3-methyl-pentanoylsu!famoyl, 5 4-methyl -pentanoylsulfamoyl, and the like.
• C 2 ⁇ alkenyl denotes a radical containing 2 to 6 carbons wherein at least one carbon-carbon double bond is present, some embodiments are 2 to 4 carbons, some embodiments are 2 to 3 carbons, and some embodiments have 2 carbons.
• E and Z isomers are embraced by the term “alkenyl.”
• alkenyl includes di- and tri-alkenyls. Accordingly, if more 10 than one double bond is present then the bonds may be all E or Z or a mixtures of E and Z.
• Examples of an alkenyl include vinyl, allyl, 2-butenyl, 3-butenyI, 2-pentenyl. 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexanyl, 2,4-hexadienyl and the like.
• C M alkoxy denotes a radical alkyl, as defined herein, attached directly to an oxygen atom. Examples include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, t- 15 butoxy, iso-butoxy, sec-butoxy and the like.
• .g alkyl denotes a straight or branched carbon radical containing 1 to 8 carbons, some embodiments are I to 6 carbons, some embodiments are 1 to 3 carbons, and some embodiments are 1 or 2 carbons.
• alkyl include, but not limited to, methyl, ethyl, n-propyl, iso- propyl, n-butyl, sec-butyl, iso-butyl, t-butyl, pentyl, iso-pentyl, t-pentyl, neo-pentyl, 1-methylbutyl
• C ⁇ alkylcarboxamido or "C 1 ⁇ alkylcarboxamide” denotes a single C M alkyl group attached to the nitrogen of an amide group, wherein alkyl has the same definition as found herein.
• the C,. 5 alkylcarboxamido may be represented by the following:
• Examples include, but not limited to, /V-methylcarboxamide, /V-ethylcarboxamide, N-n- propylcarboxamide, N-iso-propylcarboxamide, JV-n-butylcarboxamide, ⁇ -sec-butylcarboxamide, N-iso- butylcarboxamide, N-t-butylcarboxamide and the like.
• C 1 . 3 alkylene refers to a C
• C 1 .3 alkylene refers to, for example, -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, and the like.
• C,. 3 alkylene refers to -CH-, - CHCH 2 -, -CHCH 2 CH 2 -, and the like wherein these examples relate generally to "A".
• C M alkylsulfinyl denotes a C M alkyl radical attached to a sulfoxide radical of the formula: -S(O)- wherein the alkyl radical has the same definition as described herein.
• C M alkylsulfonamide refers to the groups
• C M alkyl has the same definition as described herein.
• C M alkylsulfonyl denotes a Q. 4 alkyl radical attached to a sulfone radical of the formula: -S(O) 2 - wherein the alkyl radical has the same definition as described herein. Examples include, but not limited to, methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, iso-propylsulfonyl, n- butylsulfonyl, sec-butylsulfonyl, iso-butylsulfonyl, t-butyl, and the like.
• Cu alkylth ⁇ o denotes a C M alkyl radical attached to a sulfide of the formula: -S- wherein the alkyl radical has the same definition as described herein. Examples include, but not limited to, methylsulfanyl (i.e., CH 3 S-), ethylsulfanyl, n-propylsulfanyl, iso-propylsulfanyl, n- butylsulfanyl, sec-butyls ⁇ lfanyl, iso-bulyls ⁇ lfanyl, t-butyl, and the like.
• C 1-I alkylthiocarboxamide denotes a thioamide of the following formulae: S S c, JC 1 ⁇ CL 4 alkyl A...J ⁇ _ .. . y> N N Ci. 4 alky
• C M alkyl has the same definition as described herein.
• C M alkylthioureyl denotes the group of the formula:
• alkylthioureyl examples include, but 20 not limited to, CH 3 NHC(S)NH-, NH 2 C(S)NCH 3 -, (CHj) 2 N(S)NH-, (CHj) 2 N(S)NH-, (CHj) 2 N(S)NCH 3 -, CHjCH 2 NHC(S)NH-, CH J CH 2 NHC(S)NCH J -, and the like.
• C M alkylureyl denotes the group of the formula: -NC(O)N- wherein one are both of the nitrogens are substituted with the same or different C ⁇ alkyl group wherein alkyl has the same definition as described herein.
• alkylureyl include, but not limited to,
• C 2 ⁇ alkynyl denotes a radical containing 2 to 6 carbons and at least one carbon- carbon triple bond, some embodiments are 2 to 4 carbons, some embodiments are 2 to 3 carbons, and some embodiments have 2 carbons.
• alkynyl examples include, but not limited to, ethynyl, 1 - 30 propynyl, 2-propynyl, l -butynyl, 2-butynyl, 3-butynyl, 1 -pentynyl, 2-pentynyl, 3-pentynyl, 4- pentynyl, 1 -hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl and the like.
• alkynyl includes di- and tri-ynes.
• amino denotes the group -NH 2 .
• C M alkylamino denotes one alkyl radical attached to an amino radical wherein the alkyl radical has the same meaning as described herein. Some examples include, but not limited to, methylamino, ethylamino, n-propylamino, iso-propylamino, n-butylamino, sec-butylamino, iso- butylamino, t-butylamino, and the like. Some embodiments are "C 1 .2 alkylamino.”
• aryl denotes an aromatic ring radical containing 6 to 10 ring carbons. Examples include phenyl and naphthyl.
• arylalkyl defines a C r C 4 alkylene, such as -CH 2 -, -CH 2 CH 2 - and the like, which is further substituted with an aryl group.
• Examples of an “arylalkyl” include benzyl, phenethylene and the like.
• arylcarboxamido denotes a single aryl group attached to the nitrogen of an amide group, wherein aryl has the same definition as found herein.
• the example is N-phenylcarboxamide.
• arylureyl denotes the group -NC(O)N- where one of the nitrogens are substituted with an aryl.
• benzyl denotes the group -CH 2 C 6 H 5 .
• .(,-alkoxy) refers to a C ⁇ _ 6 alkyl ester of a carboxylic acid, wherein the alkyl group is as defined herein.
• . 6 -alkoxy group is bonded to a nitrogen atom and together form a carbamate group (e.g., N-COO-C
• . 6 -alkoxy group is an ester (e.g., -COO-C
• Examples include, but not limited to, carbomethoxy, carboethoxy, carbopropoxy, carboisopropoxy, carbobutoxy, carbo-sec-butoxy, carbo- 20 iso-butoxy, carbo-t-butoxy, carbo-n-pentoxy, carbo-iso-pentoxy, carbo-t-pentoxy, carbo-neo-pentoxy, carbo-n-hexyloxy, and the like.
• carboxylate refers to the group -CONH 2 .
• carboxy or “carboxyl” denotes the group -CO 2 H; also referred to as a carboxylic acid group. 25
• cyano denotes the group -CN.
• C 3 . 7 cycloalkenyl denotes a non-aromatic ring radical containing 3 to 6 ring carbons and at least one double bond; some embodiments contain 3 to 5 carbons; some embodiments contain 3 to 4 carbons. Examples include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentenyl, cyclohexenyl, and the like.
• C 3 . 7 cycloalkyl denotes a saturated ring radical containing 3 to 6 carbons; some embodiments contain 3 to 5 carbons; some embodiments contain 3 to 4 carbons. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclopenyl, cyclohexyl, cycloheptyl and the like.
• C ⁇ s diacylamino denotes an amino group bonded with two acyl groups defined herein wherein the acyl groups may be the same or different, such as:
• C ⁇ g diacylamino groups include, but limited to, diacetylamino, dipropionylamino, acetylpropionylamino and the like.
• Cj-* dialkylamino denotes an amino substituted with two of the same or different
• alkyl radicals wherein alkyl radical has the same definition as described herein.
• Some examples include, but not limited to, dimethylamino, methylethylamino, diethylamino, methylpropylamino, methylisopropylamino, ethylpropylamino, ethylisopropylamino, dipropylamino, propylisopropylamino and the like.
• Some embodiments are "C 2 -J dialkylamino.”
• C 1 ⁇ dialkylcarboxamido or "C M dialkylcarboxamidc”denotes two alkyl 10 radicals, that are the same or different, attached to an amide group, wherein alkyl has the same definition as described herein.
• a C M dialkylcarboxamido may be represented by the following groups:
• Examples of a dialkylcarboxamide include, but 15 not limited to, ⁇ VV-dimethylcarboxamide, /V-methyl-N-ethylcarboxamide, yV,jV-diethylcarboxamide, N- methyl-N-isopropylcarboxamide, and the like.
• Cj- ⁇ dialkylsulfonamide refers to one of the following groups shown below:
• C2.6 dialkylthiocarboxamido or "C 2- * dialkylthiocarboxamide”denotes two alkyl radicals, that are the same or different, attached to a thioamide group, wherein alkyl has the same definition as described herein.
• a C M dialkylthiocarboxamido may be represented by the following groups:
• dialkylthiocarboxamide examples include, but not limited to, ⁇ / ⁇ '-dimethylthiocarboxamide, N-methyl-iV-ethylthiocarboxamide and the like.
• C 2 ⁇ dialkylsulfonylamino refers to an amino group bonded with two C 1 . 3 alkylsulfonyl groups as defined herein.
• ethynylene refers to the carbon-carbon triple bond group as represented below:
• C M haloalkoxy denotes a haloalkyl, as defined herein, which is directly attached to an oxygen atom. Examples include, but not limited to, difluoromethoxy, trifluoromethoxy, 2,2,2- trifluoroethoxy, pentafluoroethoxy and the like.
• C M haloalkyl denotes an C M alkyl group, defined herein, wherein the alky! is
• C M haloalkyl 10 substituted with one halogen up to fully substituted and a fully substituted C M haloalkyl can be represented by the formula C n L 2n+ ] wherein L is a halogen and "n" is 1, 2, 3 or 4; when more than one halogen is present then they may be the same or different and selected from the group consisting of F,
• C M haloalkyl groups include, but not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, 2,2,2-trifluoroethyl,
• C M haloalkylcarboxamide denotes an alkylcarboxamide group, defined herein, wherein the alkyl is substituted with one halogen up to fully substituted represented by the formula
• L is a halogen and "n" is 1 , 2, 3 or 4.
• n is 1 , 2, 3 or 4.
• halogen When more than one halogen is present they may be the same or different and selected from the group consisting of F, Cl, Br and I, in particular
• C 1 . 4 haloalkylsulfinyl denotes a haloalkyl radical attached to a sulfoxide group of the formula: -S(O)- wherein the haloalkyl radical has the same definition as described herein. Examples include, but not limited to, t ⁇ fluoromethylsulfinyl, 2,2,2-tr ⁇ fluoroethylsulfinyl, 2,2- difluoroethylsulfinyl and the like.
• C M haloalkylsulfonyl denotes a haloalkyl radical attached to a sulfone group of the formula: -S(O):- wherein haloalkyl has the same definition as described herein. Examples include, but not limited to, trifluoromethylsulfonyl, 2,2,2-trifluoroethylsulfonyl, 2,2- difluoroethylsulfonyl and the like.
• C M haloalkylthio denotes a haloalkyl radicaol directly attached to a sulfur 30 wherein the haloalkyl has the same meaning as described herein, Examples include, but not limited to, trifluoromethylthio (i.e., CF 3 S-), 1 ,1 -difluoroethylthio, 2,2,2-trifluoroethylthio and the like.
• halogen or “halo” denotes to a fluoro, chloro, bromo or iodo group.
• . 2 heteroalkylene refers to a C
• heteroaryl denotes an aromatic ring system that may be a single ring, two fused rings or three fused rings wherein at least one ring carbon is replaced with a heteroatom selected from, but not limited to, the group consisting of O, S and N wherein the N can be optionally substituted with H, C M acyl or C M alkyl.
• heteroaryl groups include, but not limited to, pyridyl, benzofuranyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, quinoline, benzoxazole, benzothiazole, lH-benzimidazole, isoquinoline, quinazoline, quinoxaline and the like.
• the heteroaryl atom is O, S, NH, examples include, but not limited to, pyrrole, indole, and the like.
• heterocyclic denotes a non-aromatic carbon ring (i.e., cycloalkyl or cycloalkenyl as defined herein) wherein one, two or three ring carbons are replaced by a heteroatom selected from, but not limited to, the group consisting of O, S, N, wherein the N can be optionally substituted with H, C M acyl or C 1 . 4 alkyl, and ring carbon atoms optionally substituted with oxo or a thiooxo thus forming a carbonyl or thiocarbonyl group.
• the heterocyclic group is a 3-, 4-, 5-, 6- or 7-membered
• heterocyclic group examples include but not limited to aziridin-1 -yl, aziridin-2- yl, azetidin-1 -yl, azetidin-2-yl. azetidin-3-yl, piperidin-1 -yl, piperidin-4-yl, morpholin-4-yl, piperzin- 1 -yl, piperzin-4-yl, pyrrolidin-1 -yl, pyrrolidin-3-yl, [l ,3]-dioxolan-2-yl and the like.
• heterocyclic group is bonded to the carbonyl group forming an amide.
• Examples include, but not limited to,
• a ring carbon is bonded to the c ⁇ and the like.
• heterocyclic-oxy refers to a heterocyclic group, as defined herein, that is directly bonded to an oxygen atom. Examples include the following: ⁇ - 0 V S 1
• heterocycliccarboxamido denotes a heterocyclic group, as defined herein, with a ring nitrogen where the ring nitrogen is bonded directly to the carbonyl forming an amide. Examples include, but not limited to,
• heterocyclicsulfonyl denotes a heterocyclic group, as defined herein, with a ring nitrogen where the ring nitrogen is bonded directly to an SO 2 group forming an sulfonamide. 10 Examples include, but not limited to,
• hydroxy refers to the group -OH.
• hydroxylamino refers to the group -NHOH.
• nitro refers to the group -NO 2 .
• C 4 .7 oxo-cycloalkyl refers to a C 4 . 7 cycloalkyl, as defined herein, wherein one of the ring carbons is replaced with a carbonyl.
• Examples of C 4 . 7 oxo-cycloalkyl include, but are not limited to, 2-oxo-cyclobutyl, 3-oxo-cyclobutyl, 3-oxo-cyclopentyl, 4-oxo-cyclohexyl, and the like and represented by the following structures respectively:
• perfluoroalkyl denotes the group of the formula -C n F 2n+J i stated differently, a perfluoroalkyl is an alkyl as defined herein wherein the alkyl is fully substituted with fluorine atoms and is therefore considered a subset of haloalkyl.
• perfluoroalkyls include CFj, CF 2 CF 3 , CF 2 CF 2 CF 3 , CF(CFj) 2 , CF 2 CF 2 CF 2 CF 3 , CF 2 CF(CF 3 ) 2I CF(CF 3 )CF 2 CF 3 and the like.
• phenoxy refers to the group CgH 5 O-.
• phenyl refers to the group CgH 5 -.
• sulfonamide refers to the group -SO 2 NHi.
• sulfonic acid refers to the group -SO 3 H.
• tetrazolyl refers to the five membered heteroaryl of the following formulae:
• the tetrazolyl group is further substituted at either the 1 or 5 position resepectively with a group selected from the group consisting of Q. 3 alkyl, CV 3 haloalkyl and C
• thiol denotes the group -SH.
• endogenous shall mean a material that an individual (for example, and not limitation, a human) naturally produces.
• non-endogenous shall mean that which is not naturally produced by an individual (for example, and not limitation, a human).
• host cell shall mean a cell capable of having a vector incorporated therein.
• the vector will typically contain nucleic acid encoding a GPCR or GPCR fusion protein in operable conncection with a suitable promoter sequence to permit expression of the GPCR or GPCR fusion protein to occur.
• the host cell is a eukaryotic host cell.
• the eukaryotic host cell is a mammalian host cell.
• the eukaryolic host cell is a yeast host cell.
• the eukaryotic host cell is a
• contact or "contacting” shall mean bringing at least two moieties together.
• modulate or “modify” shall be taken to refer to an increase or decrease in the amount, quality, or effect of a particular activity, function or molecule.
• agonists, partial agonists, inverse agonists, and antagonists of a G protein-coupled receptor 25 are modulators of the receptor.
• small molecule shall be taken to mean a compound having a molecular weight of less than about 10,000 grams per mole, including a peptide, peptidomimetic, amino acid, amino acid analogue, polynucleotide, polynucleotide analogue, nucleotide, nucleotide analogue, organic compound or inorganic compound (i.e. including a heterorganic compound or organometallic 30 compound), and salts, esters and other pharmaceutically acceptable forms thereof.
• small molecules are organic or inorganic compounds having a molecular weight of less than about 5,000 grams per mole.
• small molecules are organic or inorganic compounds having molecular weight of less than about 1 ,000 grams per mole.
• small molecules are organic or inorganic compounds having a molecular weight of less than about 800 grams per mole. In certain embodiments, small molecules are organic or inorganic compounds having a molecular weight of less than about 600 grams per mole. In certain embodiments, small molecules are organic or inorganic compounds having a molecular weight of less than about 500 grams per mole.
• polypeptide shall refer to a polymer of amino acids without regard to the length of the polymer.
• peptides, oligopeptides, and proteins are included within the definition of
• polypeptides that include the covalent attachment of glycosyl groups,
• polypeptide - 29 - acetyl groups, phosphate groups, lipid groups and the like are expressly encompassed by the term polypeptide.
• second messenger shall mean an intracellular response produced as a result of receptor activation.
• a second messenger can include, for example, inositol 1 ,4,5-triphosphate (IP3), diacylglycerol (DAG) 1 cyclic AMP (cAMP), cyclic GMP (cGMP), MAP kinase acitivity,
• Second messenger response can be measured for a determination of receptor activation.
• receptor functionality shall refer to the normal operation of a receptor to receive a stimulus and moderate an effect in the cell, including, but not limited to regulating gene transcription, regulating the influx or efflux of ions, effecting a catalytic reaction, and/or modulating activity through G-proteins, such as eliciting a second messenger response.
• stimulation or “stimulating,” in relationship to the term “response” or “functionality 15 of the receptor” shall mean that a response or a functionality of the receptor is increased in the presence of a compound as opposed to in the absence of the compound.
• inhibitor or “inhibiting,'” in relationship to the term “response” or “functionality of the receptor” shall mean that a response a functionality of the receptor is decreased or prevented in the presence of a compound as opposed to in the absence of the compound.
• GPRl 19 is mammalian GPR l 19. In certain embodiments, GPRl 19 is rodent or primate GPRl 19. In certain embodiments, GPRl 19 is human GPRl 19.
• the class of GPRl 19 agonists useful in compositions and methods of the present invention including but not limited to the novel therapeutic combinations of the present invention include compounds which exhibit an acceptably high affinity for GPRl 19 receptor.
• 35 pharmaceutically acceptable salt may be any agonist, and in particular embodiment a selective GPR l 19 agonist.
• GPRl 19 agonists are described in International Application No. PCT/US2004/001267 (published as WO 04/065380), the disclosure of which is herein incorporated by reference in its entirety. Disclosed in International Application No. PCT/US2004/001267 as a GPRl 19 agonist is a compound of Formula (I):
• a and B are independently C 1 . 3 alkylene optionally substituted with 1 to 4 methyl groups;
• D is O, S, S(O), S(O) 2 , CR 2 R 3 or N-R 2 ;
• 10 V is selected from the group consisting of C 1 . 3 alkylene, ethynylene and C ⁇ - 2 heteroalkylene wherein each are optionally substituted with 1 to 4 substituents selected from the group consisting of Q. 3 alkyl, C M alkoxy, carboxy, cyano, Q. 3 haloalkyl and halogen; or
• V is absent
• W is NR 4 , O, S, S(O) or S(O) 2 ; or 15 W is absent;
• X is N or CR 5 ;
• Y is N or CR 6 ;
• Z is selected from the group consisting of C
• alkylsulfonyl C M alkylthio, C M alkylthioureyl, C M alkylureyl, amino, C 1 . 2 alkylamino, C 2-4 dialkylamino, carbo-C
• . s alkyl and C 1 . 5 acyl are each optionally substituted with 1 , 2, 3 or 4 groups selected from the group consisting of C
• Z is a group of Formula (IA):
• R 7 is H, Ci-s alkyl or C 3 . 6 cycloalkyl; and Rg is H, nitro or nitrile; 5 A ⁇ is aryl or heteroaryl wherein each are optionally substituted with R 9 -R 13 ;
• R ⁇ is selected from the group consisting of H, C ⁇ . 5 acyloxy, C 2 ⁇ alkenyl, C M alkoxy, C ⁇ . % alkyl, C M alkylcarboxamide, C 2 ⁇ alkynyl, C M alkylsulfonamide, Ci -4 alkylsulfinyl, C M alkylsulfonyl, C M alkylthio, C M alkylureyl, amino, C M alkylamino, C 2 . 8 dialkylamino,
• R 2 is selected from the group consisting of H, Q. 5 acyl, Q. 5 acyloxy, Ci ⁇ alkoxy, Q.g
• haloalkyl C M haloalkylsulfinyl, C M haloalkylsulfonyl, C M haloalkyl, C M haloalkylthio, halogen, heterocyclic, hydroxyl, hydroxylamino and nitro; or
• R 2 is -Ar 2 -Ar 3 wherein Ar 2 and Ar 3 are independently aryl or heteroaryl each optionally substituted with 1 to 5 substituents selected from the group consisting of H, C 1 . 5 acyl, Q. 5 acyloxy, C M alkoxy, C
• R 2 is a group of Formula (IB):
• R 14 is C
• Ar 4 is phenyl or heteroaryl optionally substituted with 1 to 5
• R 3 is H, C
• R 4 is H or C, .s alkyl
• Rs and R 6 are independently H, Q.g alkyl or halogen
• R 9 is selected from the group consisting of C 1 . 5 acyl, Q. 5 acyloxy, C 2 . 6 alkenyl, C M alkoxy, Q. 8 alkyl, Q -4 alkylamino, C M alkylcarboxamide, C 2 _ 6 alkynyl, C M alkylsulfonamide, C M alkylsulfinyl, Q -4 alkylsulfonyl.
• heteroaryl, phenoxy and phenyl are each optionally substituted with ] to 5 substituents selected independently from the group consisting of Q. 5 acyl, Q. 5 acyloxy, C 2 . 6 alkenyl, Q -4 alkoxy, Q. 8 alkyl, Q -4 alkylcarboxamide, C 2 - 5 alkynyl, C M alkylsulfonamide, C M alkylsulfinyl, C ⁇ alkylsulfonyl, C M alkylthio, C M alkylureyl, carbo-Q. 6 -alkoxy, carboxamide, carboxy, cyano, C 3 .
• R 9 is a group of Formula (ED):
• R] 8 is H, C
• Rio-Rij are independently selected form the group consisting of C
• C 2-6 alkynyl C M alkylsulfonamide, C M alkylsulfinyl, C M alkylsulfonyl, C M alkylthio, C M alkylureyl, carbo-Ci ⁇ -alkoxy, carboxamide, carboxy, cyano.
• the present invention also encompasses diastereomers as well as optical isomers, e.g.
• GPRl 19 agonists disclosed in International Application No.
• PCT/US2004/005555 (published as WO 04/076413), the disclosure of which is herein incorporated by reference in its entirety. Disclosed in International Application No. PCT/US2004/005555 as a GPRl 19 agonist is a compound of Formula (FI):
• a and B are independently Q. 3 alkylene optionally substituted with 1 to 4 methyl groups;
• U is N or CR 1 ;
• D is O, S, S(O), S(O) 2 , CR 2 R 3 or NR 2 ;
• V is selected from the group consisting of Q.3 alkylene, ethynylene and C]. 2 heteroalkylene optionally substituted with 1 to 4 substituents selected from the group consisting of C 1 . 3 alkyl, C M alkoxy, carboxy, cyano, Q.3 haloalkyl and halogen; or V is absent;
• W is -S(O) 2 NR 4 -, -NR 4 -, -O-, -S-, -S(O)-, -S(O) 2 -; or W is absent;
• Z is selected from the group consisting of H, C
• dialkylsulfonamide C M dialkylsulfonylamino, formyl, C ⁇ ⁇ haloalkoxy, C M haloalkyl, C M haloalkylcarboxamide, CM haloalkylsulfinyl, C) ⁇ haloalkylsulfonyl, C M haloalkylthio, halogen, aryl, heteroaryl, hydroxyl, hydroxylamino, nitro and tetrazolyl; or
• Z is a group of Formula (HA):
• R 7 is H, C 6 alkyl or C 3 -* cycloalkyl; and R 8 is H, nitro or cyano; 5 Ari is aryl or heteroaryl optionally substituted with R 9 , Rio, Rn- Rn and R ⁇ ;
• Ri, R 5 and R 6 are independently selected from the group consisting of H, C 1 . 5 acyloxy, C 2 ⁇ alkeny), C M alkoxy, Ci.g alkyl, C M alkylcarboxamide, C 2-6 alkyny), C M alkylsulfonamide, Ci -4 alkylsulfinyl, C M alkylsulfonyl, C M alkylthio, C ⁇ alkylureyl, amino, C M alkylamino, C 2 . 8 dialkylarnino, carboxamide, cyano, C 3 .
• R 2 is selected from the group consisting of H, C 1 . 5 acyl, Q. 5 acyloxy, C M alkoxy, C
• alkylsulfinyl C M alkylsulfonyl, C M alkylthio, C1-4 alkylthioureyl, C M alkylureyl, amino, carbo-
• R 2 is -Ar 2 -Ar 3 wherein Ar 2 and Ar 3 are independently aryl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of H, Ci -5 acyl, C
• R 2 is a group of Formula (IIB):
• Ri 4 is C
• Ar 4 is phenyl or heteroaryl optionally substituted with 1 to 5
• R 3 is H. C
• R 4 is H or C
• Rg is selected from the group consisting of C
• C ⁇ ⁇ haloalkyl C ⁇ ⁇ haloalkylsulfinyl, C ⁇ ⁇ haloalkylsulfonyl, C M haloalkylthio, heterocyclic, heterocyclicsulfonyl, heteroaryl, hydroxyl, nitro, C 4-7 oxo-cycloalkyl, phenoxy, phenyl, sulfonamide and sulfonic acid, and wherein C 1 .
• acyl C M alkoxy, Q.s alkyl, C M alkylsulfonamide, alkylsulfonyl, arylsulfonyl, heteroaryl, phenoxy and phenyl are optionally substituted with 1 to 5 substituents selected independently from the group consisting of Q. 5 acyl,
• R 9 is a group of Formula (IID):
• Ri 8 is H 1 C 1 . 5 acyl, C 2 . 6 alkenyl, Q. 8 alkyl, C M alkylcarboxamide, C 2 ⁇ alkynyl, C M alkylsulfonamide, carbo-C
• R ⁇ o-Ri 3 are independently selected form the group consisting of C 1 . 5 acyl, C
• two adjacent R ⁇ o-R ⁇ 1 groups form a 5, 6 or 7 membered cycloalkyl, cycloalkenyl or heterocyclic group with Ari wherein the 5, 6 or 7 membered group is optionally substituted with halogen.
• the present invention also encompasses diastereomers as well as optical isomers, e.g. mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and
• GPRl 19 agonists disclosed in International Application No.
• PCT/US2004/005555 include the following compounds according to Formula (II) (referred to herein
• GPRl 19 agonists disclosed in International Application No. PCT/US2OO4/OO5555 include the following compounds according to Formula (II) (referred to herein as Group B2): l -[5-(4-Benzoyl-phenoxy)-2-nitro-phenyl]-piperidine-4-carboxylic acid ethyl ester; 1 -
• PCT/US2004/005555 include the following compound according to Formula (II) (referred to herein as Group B3): 5-Bromo-l -[4-nitro-3-(4-propyl-piperidin-l -y))-phenyl]-l H-pyridin-2-one.
• GPRl 19 agonists disclosed in International Application No. PCT/US2004/005555 include the following compounds according to Formula (II) (referred to herein as Group B4): o'-Benzenesulfonylamino-S'-nitro-S ⁇ -tetrahydro ⁇ H-ll ⁇ 'lbipyridinyM-carboxylic
• GPRl 19 agonists disclosed in International Application No. PCT/US2004/005555 include the following compounds according to Formula (II) (referred to herein
• GPRl 19 agonists are described in International Application No. PCT/US2004/022327 (published as WO 05/007647), the disclosure of which is herein incorporated by reference in its entirety. Disclosed in International Application No. PCT/US2004/022327 as a GPRl 19 agonist is a compound of Formula (HI):
• a and B are each independently Q.j alkylene optionally substituted with I to 4 substituents selected from the group consisting of C] . 3 alkyl, Q -4 alkoxy, carboxy, cyano, Q. 3 haloalkyl and halogen;
• D is O, S, S(O), S(O) 2 , CR 2 R 3 or N-R 2 ;
• E is N, C or CR 4 ;
• — is a single bond when E is N or CR 4 , or a double bond when E is C;
• is selected from the group consisting of C 1 . 3 alkylene, ethynylene and Q. 2 heteroalkylene optionally substituted with 1 to 4 substituents selected from the group consisting of C 1 . 3 alkyl, Q -4 alkoxy, carboxy, cyano, Q. 3 haloalkyl and halogen; or V
• V 2 is C 3 . 6 cycloalkylene or Q. 3 alkylene wherein each are optionally substituted with I to 4 substituents selected from the group consisting of C 1 .3 alkyl, C M alkoxy, carboxy, cyano, C
• W is NR 5 , O, S, S(O) or S(O) 2 ; or W is absent;
• Q is NR 6 , O, S, S(O) or S(O) 2 ;
• X is N or CR 7 ;
• Y is N or CR 8 ;
• Z is selected from the group consisting of Q. 5 acyl, Ci -5 acyloxy, C 2 ⁇ alkenyl, C M alkoxy, Q. 3 alkyl, C M alkylcarboxamide, C 2 * alkynyl, C M alkylthiocarboxamide, C M alkylsulfonamide, C M alkylsulfinyl, C M alkylsulfonyl, Q -4 alkylthio, C M alkylthioureyl, C t-4 alkylureyl, amino, Q.
• . s alkyl, C 3 . ? cycloalkyl, and heterocyclic are each optionally substituted with 1 , 2, 3 or 4 groups selected from the group consisting of C 1 . 5 acyl, C 1 . 5 acyloxy, Q -4 alkoxy, C
• R 9 is H, Ci-s alkyl or C3.7 cycloalkyl
• Ari is aryl or heteroaryl each optionally substituted with Rn, R ⁇ , R 13 , Ru, and Ri 5 ; wherein Rn is selected from the group consisting of C 1 . 5 acyl, C ⁇ . 6 acylsulfonamide, Q.
• heteroaryl heteroarylcarbonyl, hydroxyl, nitro, C 4-7 oxo-cycloalkyl, phenoxy, phenyl, sulfonamide, sulfonic acid, and thiol, and wherein Q. 5 acyl, C). 6 acylsulfonamide, C) ⁇ alkoxy, C
• 6 dialkylamino, heterocyclic, heterocyclic-carbonyl, heteroaryl, phenoxy and phenyl are optionally substituted with 1 to 5 substituents selected independently from the group consisting of C
• Rn is a group of Formula (IHB):
• 6 is H, C
• 5 are each independently selected form the group consisting of C,. 5 acy], C 1S acyloxy, C 2 ⁇ alkenyl, C 1 ⁇ , alkoxy, Q.s alk>'l, C 1 ⁇ alkylcarboxamide, C 2 . ⁇ alkynyl, Ci -4 alkylsulfonamide, Ci -4 alkylsulfinyl, C M alkylsulfonyl, C M alkylthio, C M alkylureyl, carbo-C, ⁇ - alkoxy, carboxamide, carboxy, cyano, C 3 .
• R ⁇ , R 7 and R 8 are each independently selected from the group consisting of H, C
• R 2 is selected from the group consisting of C
• R 2 is -Ar 2 -Ar 3 wherein Ar 2 and Ar 3 are each independently aryl or heteroaryl optionally substituted with 1 to 5 substituents selected from the group consisting of H, C
• R 2 is a group of Formula (HIC):
• Ri 7 is H, Ci. 8 alkyl, C 3-7 cycloalkyl, aryl, heteroaryl or OR 19 ; and R, 8 is F, Cl, Br, CN or NR 20 R 2I i where R 19 is H, Q.s alkyl or C 3 . 7 cycloalkyl, and R 2 o and R 21 are each independently H, Q. 8 alkyl, C 3 . 7 cycloalkyl, aryl or heteroaryl; or
• R 2 is a group of Formula (1IED):
• G is: i) -C(O)-, -C(O)NR 23 -, -C(O)O-, -OC(O)NR 23 -, -NR 23 C(O)O-, -OC(O) -,
• R 22 is H, Q -8 alkyl, C 2 ⁇ alkynyl, O 3 . 7 cycloalkyl, phenyl, heteroaryl, or heterocyclic each optionally substituted with 1 to 5 substituents selected from the group consisting of Q. 5 acyl, C
• R 3 is H, C
• R,, R 5 and R 6 are each independently H, C
• the present invention also encompasses diastereomers as well as optical isomers, e.g. mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds of the invention. Separation of the individual isomers or selective synthesis of the individual isomers is 5 accomplished by application of various methods which are well known to practitioners in the art.
• PCTAJ S2004/022327 include the following compounds according to Formula (FII) (referred to herein as Group Cl): 3-[6-(4-Methanesulfonyl-phenylamino)-5-nitro-pyrirnidin-4-yloxymethyl]- pyrrolidine-l -carboxylic acid tert-butyl ester; 4-[5-Cyano-6-(6-methylsulfanyl-py ⁇ din-3-y!amino)-
• GPRl 19 agonists disclosed in International Application No. PCT/US2004/022327 include the following compounds according to Formula (III) (referred to herein as Group C2): 4-[6-(4-MethanesulfonyI-phenylamino)-5-nitro-pyrirnidin-4-yloxy]-piperidine-l - carboxylic acid tert-butyl ester; (4-Methanesulfonyl-phenyl)-[5-nitro-6-(piperidin-4-yloxy)-pyrimidin-
• PCT/US2004/022327 include the following compounds according to Formula (IH) (referred to herein as Group C3): 4-[6-(4-Methanesulfonyl-phenylamino)-5-nitro-pyrimidin-4-ylamino]-piperidine-l -
• PCT/US2004/022327 include the following compounds according to Formula (III) (referred to herein as Group C4): 4-[6-(4-Cyano-2-fluoro-phenylamino)-5-ethynyl-pyrimidin-4-yloxy]-piperidine-l - carboxylic acid isopropyl ester; 4-[5-Ethynyl-6-(2-fluoro-4-[l ,2,4]triazol-l -yl-phenylamino)- pyrimidin-4-yloxy]-piperidine-l-carboxylic acid isopropyl ester; 4- ⁇ 5-Ethynyl-6-[l -(3-isopropyl-
• PCT ⁇ JS2004/022327 include the following compounds according to Formula (HI) (referred to herein as Group CS): 4-[5-Acetyl-6-(6-methanesulfonyl-pyridin-3-ylamino)-pyrimidin-4-yloxy)-piperidine- I -carboxylic acid isobutyl ester; l -[4-( l -Benzyl-azetidin-3-yloxy)-6-(6-methanesulfonyl-pyridin-3- ylamino)-pyrimidin-5-yl]-ethanone; 4-[5-Cyano-6-(6-propylamino-pyridin-3-ylamino)-pyrirnidin-4-
• 35 carboxylic acid isopropyl ester; 4- ⁇ 5-Cyano-6-[4-(2-dimethylamino-ethylsulfanyl)-2-fluoro- phenylamino]-pyrimidin-4-yloxy )-piperidine- l -carboxylic acid isopropyl ester; 4- ⁇ 5-Cyano-6-[4-(2- dimethylamino-ethanesulfonyl)-2-fluoro-phenylamino]-3-oxy-pyrimidin-4-yloxy )-piperidine-l -
• 25 isopropyl ester; 4-[6-(4-Cyano-2-fluoro-phenylamino)-5-methyl-pyrimidin-4-yloxy]-piperidine-l - carboxylic acid isopropyl ester; 4-[6-(4-Cyano-2,5-difluoro-phenylamino)-5-methyl-pyrimidin-4- yloxy]-piperidine-l -carboxylic acid isopropyl ester; 4-[6-(2,5-Difluoro-4-mo ⁇ holin-4-yl- phenylamino)-5-methyl-pyrimidin-4-yloxy]-piperidi ⁇ e-l -carboxylic acid isopropyl ester; 4-[6-(6- Ch loro-2-methyl-pyridin-3-ylamino)-5-methyl-pyrimidin-4-yloxy)-piperidine-l -carboxylic acid
• piperidine- 1 -carboxylic acid isopropyl ester; 4-[6-(6-Chloro-4-fluoro-pyridin-3-ylamino)-5-cyano- pyrimidin-4-yloxy]-piperidine-l -carboxylic acid isopropyl ester; and 4-[5-Amino-6-(2-fluoro-4- methanesulfonyl-phenylamino)-pyrimidin-4-yloxy]-piperidine-l -carboxylic acid isopropyl ester.
• GPR l 19 agonists disclosed in International Application No. PCT ⁇ JS2004/022327 include the following compound according to Formula (III) (referred to herein
• GPRl 19 agonists disclosed in International Application No. PCT7US2004/022327 include the following compounds according to Formula (III) (referred to herein as Group C7): 4-(2-Fluoro-4-methanesuIfonyl-phenoxy)-6-[I -(3-methoxy-propyl)-piperidin-4- yloxy]-5-methyl-pyrimidine; l - ⁇ 4-[6-(2-FIuoro-4-methanesulfonyl-phenoxy)-5-methyl-pyrimidin-4- 5 yloxy]-piperidin-l -yl ) -3-methoxy-propan-2-ol; 4- ⁇ 6-[2-Fl uoro-4-(5-isopropoxy methyl- f l ,2/l]oxadiazol ⁇ 3-yl)-phenoxy]-5-methyl-pyrimidin-4-yloxy) -piperidine- 1 -carboxylic acid is
• GPRl 19 agonists disclosed in International Application No.
• 25 PCT/US2004/022327 include the following compounds according to Formula (III) (referred to herein as Group C8): 4-[6-(2-Fluoro-4-mo ⁇ holin-4-yl-phenoxy)-5-methyl-pyrimidin-4-yloxy]-piperidine-l - carboxylic acid isopropyl ester; ⁇ 4-[6-(2-Fluoro-4-methanesulfonyl-phenoxy)-5-methyl-pyrimidin-4- yloxy]-piperidin-l -yl ) -[6-(2-pyrrolidin-l -yl-ethyl)-pyridin-3-yl]-methanone; (6-Amino-pyridin-3-yl)- ⁇ 4-[6-(2-fluoro-4-methanesulfonyl-phenoxy)-5-methyl-pyrimidin-4-yloxyJ-piperidin-l -yl ⁇ -
• 35 isopropyl ester; 4-[5-Methyl-6-(2-methyl-6-pentyl-pyridin-3-yloxy)-pyrimidin-4-yloxy]-piperidine-l- carboxylic acid isopropyl ester; 2- ⁇ 4-L6-(2-Fluoro-4-methanesulfonyl-phenoxy)-5-methyl-pyrimidin- 4-yloxy]-piperidin-l -yl ⁇ -l -(3-fluoro-phenyl)-ethanone; 4-(2-Fluoro-4-methanesulfonyl-phenoxy)-5-
• GPR I 19 agonists disclosed in International Application No. PCT/US2004/022327 include the following compounds according to Formula (III) (referred to herein as Group C9): 4-( ⁇ Cyclopropyl-[6-(2-fluoro-4-methanesulfonyl-phenoxy)-5-methyl-pyrimidin-4-ylJ-
• GPR l 19 agonists disclosed in International Application No. PCT/US2004/022327 include the following compound according to Formula (III) (referred to herein as Group ClO): 4-[6-(2-Fluoro-4-methanesulfonyl-phenylamino)-5-methyl-pyrimidin-4-ylsulfanyl)- piperidine-1 -carboxylic acid isopropyl ester.
• GPRl 19 agonists are described in International Application No.
• a and B are each independently C
• - 61 - D is O, S, S(O), S(O) 2 , CR 1 R 2 or N-R 3 , wherein Ri is selected from the group consisting of H, Ci- B alkyl, Ci -4 alkoxy, halogen and hydroxyl;
• E is N, C or CR 3 , wherein R 3 is H or C,. s alkyl; — is a single bond when E is N or CR 3 , or a double bond when E is C;
• K is a C 3 ⁇ cycloalkylene or C
• Q is NR 4 , O, S, S(O) or S(O) 2 , wherein R 4 is H or Q.g alkyl and the C ⁇ alkyl is optionally substituted with C 2 .s dialkylamine;
• T is N or CR 5 ;
• M is N or CR 6 ;
• J is N or CR 7 ;
• U is C or N
• V is N, CRs or V is a bond; W is N or C;
• X is O, S, N, CRo Or NR n ;
• Y is O, S, N, CRio or NR 12 ; Z is C or N;
• 0 are each independently selected from the group consisting of H, C 1 . 5 acyloxy, C 2 ⁇ , alkenyl, Q -4 alkoxy, Cj.g alkyl, C M alkylcarboxamide, C 2-6 alkynyl, C M alkylsulfonamide, C M alkylsulfinyl, C M alkylsulfonyl, C M alkylthio, C M alkylureyl, amino, C M alkylamino, C 2 . 8 dialkylamino, carboxamide, cyano, C 3 ⁇ cycloalkyl, C 2 ⁇ dialkylcarboxamide, C 2 .
• 2 are each independently selected from C 2 . ⁇ alkenyl, C
• An is aryl or heteroaryl each optionally substituted with Ri 3 , Ru, R
• 6 dialkylamino, heterocyclic, heterocyclic-carbonyl, heteroaryl, phenoxy and phenyl are optionally substituted with 1 to 5 substituents selected independently from the group consisting of Q. 5 acyl, C ⁇ .$ acyloxy, C 2 ⁇ alkenyl, C M alkoxy, C1.7 alkyl, C)-4 alkylamino, C M alkylcarboxamide, C 2 -6 alkynyl, Ci -4 alkylsulfonamide, C ⁇ ⁇ alkylsulfinyl, C M alkylsulfonyl, C 1-4 alkylthio, C M alkylureyl, carbo-C
• Ci -7 alkyl and C M alkylcarboxamide are each optionally substituted with I to 5 substituents selected from the group consisting of C ⁇ ⁇ alkoxy and hydroxy; or
• Ri 3 is a group of Formula (FVA):
• Ri 6 is H, C1.5 acyl, C 2 . 6 alkenyl, C
• Rj 4 , R is. Ri 6 . and R 17 are each independently selected form the group consisting of H, Q. 5 acyl, C, . 5 acyloxy, C 2 ⁇ alkenyl, C M alkoxy, C,. 8 alkyl, Q -4 alkylcarboxamide, C 2 ⁇ alkynyl, Q -4 alkylsulfonamide, C M alkylsulfinyl, Ci -4 alkylsulfonyl, C M alkylthio, CM alkylureyl, carbo-C
• R 2 is selected from the group consisting of C
• R 2 is -Ar 2 -Ar 3 wherein Ar 2 and Ar 3 are each independently aryl or heteroaryl each optionally substituted with 1 to 5 substituents selected from the group consisting of H, C 1 ⁇ acyl, C1.5 acyloxy, C M alkoxy, CI.
• R 2 is a group of Formula (IVB):
• Ri9 is H, C
• R 2 is a group of Formula (IVC):
• G is: i) -C(O)-, -C(O)NR 23 -, -NR 25 C(O)-, -NR 25 -, -NR 25 C(O)O-,
• R 25 , R 26 and R 27 are each independently H or C
• cycloalkyl C 2 _s dialkylamino, C 2-6 dialkylcarboxamide, C 2 ⁇ dialkylthiocarboxamide, C 2 ⁇ dialkylsulfonamide, C M alkylthioureyl, C M haloalkoxy, C M haloalkyl, C M haloalkylsulfinyl, Q -4 haloalkylsulfonyl, C M haloalkyl, Q -4 haloalkylthio, halogen, heterocyclic, hydroxyl, hydroxylamino, nitro, and phenyl; provided that Z and U are not both N.
• the present invention also encompasses diastereomers as well as optical isomers, e.g. mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds of the invention. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art.
• GPRl 19 agonists disclosed in International Application No. PCT/US2004/022417 include the following compounds according to Formula (IV) (referred to herein as Group Dl): 4-(l-(4-Methanesulfony]-phenyl)-lH-pyrazolo[3,4-d]pyrimidin-4-yloxy]-piperidine-l- carboxylic acid tert-butyl ester; 4-[l -(4-Methanesulfony l-phenyl)-3-methyl-lH-pyrazoIo[3,4- 5 d]pyrimidin-4-yloxy]-piperidine-l -carboxylic acid tert-butyl ester; 4-[l-(4-Methanesulfonyl-phenyI)- 3,6-dimethyl-lH-pyrazolo[3,4-d]pyrimidin-4-yloxy]-piperidine-l -carboxylic acid
• 25 isopropyl ester; 4-[l -(4-Methanesulfony l-phenyl)- 1 H-pyrazolo[3,4-d]pyrimidin-4-yloxy]-piperidine- 1-carboxylic acid butyl ester; 4-[l -(4-Methanesulfbnyl-phenyl)-lH-pyrazolo[3,4-d]pyrirnidin-4- yloxy]-piperidine-l -carboxylic acid propyl ester; 4-[l -(3-Fluoro-phenyl)-lH-pyrazolo[3,4- d)pyrimidin-4-yloxy]-piperidine- l -carboxylic acid tert-butyl ester; 4-[ l -(2,4-Difluoro-phenyl)-l H- pyrazolo[3,4-d]pyrimidin-4-yloxy]-piper
• esteracid tert-butyl ester 4-[l -(4-Methanesulfonyl- pheny I)- l H-pyrazolo[3,4-d]pyrimidin-4-yloxy]-piperidine-l -carboxylic acid 2-pyridin-3-yl-ethyl ester; 4-[ l -(4-Methanesulfonyl-phenyl)-lH-pyrazolo[3,4-d]pyrimidin-4-yloxy]-piperidine-l - carboxylic acid 3-pyridin-3-yl-propyl ester; 4-[l -(4-Methanesulfonyl-phenyl)-lH-pyrazolo[3,4-
• PCT/US2004/022417 include the following compounds according to Formula (IV) (referred to herein as Group D2): 4-(( [l-(2,5-Difluoro-phenyl)-IH-pyrazolo[3,4-d]pyrimidin-4-yl]-methyl-amino ⁇ - methyl)-pipe ⁇ dine-l -carboxylic acid tert-butyl ester; 2- ⁇ 4-[l -(2-Fluoro-4-methanesuIfonyl-phenyl)- IH-pyrazolo[3,4-d]pyrimidin-4-yloxy]-piperidin-l -yl ⁇ - l-(4-trifIuoromethoxy-phenyl)-ethanone; 2-
• GPR l 19 agonists disclosed in International Application No. PCT7US2004/022417 include the following compounds according to Formula (IV) (referred to herein as Group D3): 4-[9-(6-Methanesulfonyl-pyridin-3-yl)-9H-purin-6-yloxy]-piperidine-l-carboxylic acid isobutyl ester; ⁇ 4-[9-(6-Methanesulfonyl-pyridin-3-yl)-9H-purin-6-yloxy]-piperidin-l -yl ⁇ - 5 pyridin-3-yl-methanone; 4-[9-(4-Methanesulfonyl-phenyl)-9H-purin-6-yloxy]-piperidine-l-carboxylic acid tert-butyl ester; 4-[9-(6-Methanesulfonyl-pyridin-3-yl)-9H-piperidine-l-car
• PCT/US2004/022417 include the following compounds according to Formula (IV) (referred to herein as Group D4): 4-[9-(2-Fluoro-4-propionylsulfamoyl-phenyl)-9H-purin-6-yloxy]-piperidine-] - carboxylic acid isopropyl ester; 4-[9-(4-Cyano-2-fluoro-phenyl)-9H-purin-6-yloxy]-piperidine-l- carboxylic acid isopropyl ester; 4-[9-(2-Fluoro-4-sulfamoyl-phenyl)-9H-purin-6-yloxyJ-piperidine-l - carboxylic acid isopropyl ester; 9-(2-Fluoro-4-methanesulfonyl-phenyl)-6- ⁇ -(3-isopropyl-
• GPRl 19 agonists disclosed in International Application No. PCT/US2004/022417 include the following compound according to Formula (IV) (referred to herein as Group D5): 4-[3-(4-Methanesulfonyl-phenyI)-3H-[l ,2,3]triazolo[4,5-d]pyrimidin-7-yloxy]- piperidine-1 -carbpxylic acid tert-butyl ester.
• PCT/US2004/022417 include the following compounds according to Formula (IV) (referred to herein as Group D6): 3-(2-Fluoro-4-methanesulfonyl-phenyl)-7-[l-(3-isopropyl-[l ,2,4]oxadiazol-5-yl)- piperidin-4-yloxy]-3H-[l ,2,3]triazolo[4,5-d]pyrimidine; 3-Fluoro-4- ⁇ 7-[l -(3-isopropyl-
• PCT/US2004/022417 include the following compound according to Formula (IV) (referred to herein as Group D7): 4-[3-(4-Methanesulfonyl-phenyl)-isoxazolo[4,5-d]pyrimidin-7-yloxy]-piperidine-l - carboxylic acid tert-butyl ester.
• PC17US2004/022417 include the following compounds according to Formula (IV) (referred to herein as Group D8): 4-( ⁇ Ethyl-[3-(4-methanesulfonyl-phenyl)-isoxazolo[4,5-d]pyrimidin-7-yl]-amino ⁇ - methyl)-piperidine-t-carboxylic acid tert-butyl ester; 4-[3-(4-Methanesulfonyl-phenyl)-isoxazolo[4,5- d]pyrimidin-7-ylsulfanyl]-piperidine-l -carboxylic acid tert-butyl ester; and 4-[3-(4-Methanesulfonyt- phenyl)-isoxazoIo[4,5-d]pyrimidin-7-yloxy]-piperidine-l -carboxylic acid isopropyl ester.
• Formula (IV) referred to herein as
• PCT/US2004/022417 include the following compound according to Formula (IV) (referred to herein as Group D9): 4-[8-(2-Fluoro-4-methanesulfonyl-phenyl)-[l ,7]naphthyridin-4-yloxy]-piperidine-l- carboxylic acid isopropyl ester.
• GPRl 19 agonists disclosed in International Application No.
• 20 PCT/US2004/022417 include the following compounds according to Formula (IV) (referred to herein as Group DlO): 4-[8-(2-Fluoro-4-methanesulfonyl-phenyl)-quinolin-4-yloxy]-piperidine-l -carboxylic acid isopropyl ester; 4-[8-(4-Methylsulfanyl-phenyl)-quinolin-4-yloxy]-piperidine-l -carboxylic acid isopropyl ester; 4-[8-(4-Methanesulfonyl-phenyl)-quinolin-4-yloxy]-piperidine-1 -carboxylic acid isopropyl ester; 4-[S-(4-Isopropoxy-phenyl)-quinolin-4-yloxy]-piperidine-l -carboxylic acid isopropyl
• PCT/US2004/022417 include the following compounds according to Formula (IV) (referred to herein as Group DlI): 4-f8-(2-Fluoro-4-methanesuIfonyJ-phenyl)-py ⁇ do[3,4-d]pyrimidin-4-yloxyj- piperidine-1 -carboxylic acid isopropyl ester; 4-[8-(2-Fluoro-4-propionylsulfamoyl-phenylV pyrido[3,4-d]pyrimidin-4-yloxy]-piperidine- l -carboxylic acid isopropyl ester; 4-[8-(4-Cyano-2-
• GPRl 19 agonists disclosed in International Application No. PCT/US2004/022417 include the following compounds according to Formula (IV) (referred to herein as Group D12): 3-(2-Fluoro-4-methanesulfonyl-phenyl)-7-[4-(3-isopropyl-[l ,2,4]oxadiazol-5-yl)- cyc!ohexyloxy]-pyrazolo[ l ,5-a]pyrimidine; 3-Fluoro-4- ⁇ 7-[4-(3-isopropyl-[l ,2,4]oxadiazol-5-yl)-
• 35 isopropyl-[l ,2,4]oxadiazol-5-yl)-piperidin-4-yloxy]-pyrazolo[l ,5-a]pyrimidin-3-yl ⁇ -N-propionyl- benzenesulfonamide; 3-Fluoro-4- ⁇ 7-[l -(3-isopropyl-[l ,2,4]oxadiazol-5-yl)-piperidin-4-yloxy]- pyrazolo[l ,5-a]pyrimidin-3-yl ⁇ -benzonitrile; 3-Fluoro-4- ⁇ 7-[l -(3-isopropyl-[l ,2,4]oxadiazol-5-yl)-
• GPRl 19 agonists disclosed in International Application No. 5 PCT/US2004/022417 include include the following compounds according to Formula (IV) (referred to herein as Group D13): 4-[3-(2-Fluoro-4-methanesulfonyl-phenyl)-l -methyl-lH-pyrazolo[4,3- d]pyrimidin-7-yloxy]-piperidine-l -carboxylic acid isopropyl ester; 4-[3-(2-Fluoro-4- propionylsulfamoyl-phenyl)- l -methyl- 1 H-pyrazolo[4,3-d]pyrimidin-7-yloxy)-piperidine-l-carboxylic acid isopropyl ester; 4-[3-(4-Cyano-2-fluoro-phenyl)-l -methyI- lH-pyrazolo[4,3-d]pyrimidin-7-
• GPRl 19 agonists disclosed in International Application No. 5 PCT/US2004/022417 include the following compounds according to Formula (IV) (referred to herein as Group D14): 4-[3-(2-Fluoro-4-methanesulfonyl-phenyl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-7- yloxy]-piperidine-l -carboxylic acid isopropyl ester; 4-[3-(2-Fluoro-4-propionyIs ⁇ lfamoyl-phenyl)-2- methyl-2H-pyrazolo[4,3-d)pyrimidin-7-yloxy]-piperidine-l -carboxylic acid isopropyl ester; 4-[3-(4- Cyano-2-fluoro-phenyl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-7-yloxy]-piperidine- l -carboxylic acid
• GPRl 19 agonists are described in International Application No. PCT/US2005/019318 (published as WO 2005/121 121), the disclosure of which is herein incorporated 5 by reference in its entirety. Disclosed in International Application No. PCT/US2005/019318 as a GPRl 19 agonist is a compound of Formula (V):
• and Ai are independently C].
• 3 alkylene optionally substituted with one or more substituents selected independently from the group consisting of C, ⁇ alkyl, C
• D is CRiR 2 or NR 2 , wherein R
• 15 E is N, C or CR 3 , wherein R 3 is H or C ⁇ alkyl;
• — is a single bond when E is N or CR 3 , or a double bond when E is C; K is absent, C 3 . ⁇ cycloalkylene, or C). 3 alkylene group optionally substituted with one or more substituents selected independently from the group consisting of Q -6 alkyl, C 1 ⁇ alkoxy, carboxy, cyano, and halogen;
• Qi is NR 4 , O, S, S(O) or S(O) 2 , wherein R 4 is H, Q -6 acyl, C,. 6 alkyl, C 2 ⁇ alkenyl, C 2 - O alkynyl, C 3 .? cycloalkyl, or C 3 . 7 -cycloalkyl-C
• Q 2 is absent, NR 5 , or O, wherein R 5 is H 1 C
• C ⁇ acyl is optionally substituted with one or more substituents selected independently from the group consisting of C ⁇ acyl, Q_ 5 acyloxy, C 2 . 6 alkenyl, C[. 6 alkoxy, C w alkyl, C 1-6 alkylamino, Q -6 alkylcarboxamide, C 2 . 6 alkynyl, Ci ⁇ alkylsulfonamide, C ⁇ - 6 alkylsulfinyl, Ci ⁇ alkylsulfonyl, C w alkylthio, Ci- ⁇
• X is N or CR 6 ;
• Y is N or CR 7 ;
• Z is N or CR 5 ;
• V is absent, C 1 . 3 heteroalkylene, or C 1 . 3 alkylene wherein each are optionally substituted 10 with one or more substituents selected independently from the group consisting of C1.3 alkyl, C 1 ⁇ alkoxy, carboxy, cyano, Q. 3 haloalkyj, and halogen;
• R 0 , R7, and Rs are each independently selected from the group consisting of H, d.6 acyl, C L6 acyloxy, C 2-6 alkenyl, C L6 alkoxy, C
• alkylthiocarboxamide C
• Ar is aryl or heteroaryl optionally substituted with R 9 -R 13 ;
• R 9 is selected from the group consisting of Q. ⁇ acyl, Ci ⁇ acyloxy, C 2 . 6 alkenyl, Q -6 alkoxy, C L6 alkyl, C L6 alkylamino, C )-6 alkylcarboxamide, C 2 . 6 alkynyl, C ⁇ -6 alkylsulfonamide,
• each available R 9 is optionally substituted with one or more substituents selected independently from the group
• haloalkylsulfmyl Ci ⁇ haloalkylsulfonyl, Ci ⁇ , haloalkylthio, heteroaryl, heteroarylcarbonyl, heteroarylsulfonyl, heterocyclic, hydroxyl, hydroxylamino, and nitro;
• R ⁇ o-Ri 3 are independently selected from the group consisting of Ci ⁇ acyl, C ⁇ .(, acyloxy,
• haloalkylsulfonyl C ⁇ haloalkylthio, hydroxyl, hydroxylamino, nitro, and thiol; or two adjacent groups together with the atoms to which they are bonded form a 5, 6 or 7 member cycloalkyl, cycloalkenyl or heterocyclic group wherein the 5, 6 or 7 member group is optionally substituted with halogen or oxo; and
• R 2 is selected from the group consisting of H, C ⁇ acyl, Ci. ⁇ acyloxy, C 2-6 alkenyl, Cu
• 6 alkyl is further optionally substituted with one or more substituents selected independently from the group consisting of C h6 acyl, C- 1 . 5 alkoxy, Q- ⁇ alkylamino, Ci-s
• the present invention also encompasses diastereomers as well as optical isomers, e.g. mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds of the invention. Separation of the individual isomers or selective synthesis of the individual isomers is
• GPR I 19 agonists disclosed in International Application No. PCT ⁇ JS2005/019318 include the following compounds according to Formula (V) (referred to herein as Group El): 4-[4-(3-Isopropyl-[] ,2,4]oxadiazol-5-yl)-piperidin- l -yl]-6-(4-methanesulfonyi- phenoxy)-p ⁇ rimidine; (6-[4-(3-Isopropyl-[l ,2,4]oxadiazol-5-yl)-piperidin-l -yI]-pyrimidin-4-yl ⁇ -(4-
• GPR l 19 agonists disclosed in International Application No. PCT/US2005/019318 include the following compounds according to Formula (V) (referred to herein
• Group E2 4-[6-(2-Fluoro-4-methanesulfonyl-phenylamino)-pyrimidin-4-yloxy]-piperidine-l - carboxylic acid tert-butyl ester; (2-Fluoro-4-methanesulfonyl-phenyl)-(6-[l -(3-isopropyl- [ l ,2,4]oxadiazol-5-ylmethyl)-piperidin-4-yloxy]-pyrimidin-4-yl ⁇ -amine; 4-[6-(2-Fluoro-4- methanesulfonyl-phenylamino)-pyrimidin-4-yloxy]-piperidine-l -carboxylic acid isopropyl ester; (6- Chloro-pyridin-2-yl)- ⁇ 4-[6-(2-fluoro-4-methanesulfonyl-phenylamino)-pyrimidin-4
• 25 isopropyl ester; 4-[6-(4-Dimethylamino-2-fluoro-phenylamino)-pyrimidin-4-yloxy]-piperidine-l - carboxylic acid isopropyl ester; 4-[6-(2-Fluoro-4-propylamino-phenylamino)-pyrimidin-4-yloxy]- piperidine-1 -carboxylic acid isopropyl ester; 4-[6-(2-Fluoro-4-isopropylamino-phenylamino)- pyrimidin-4-yloxy]-piperidine-l -carboxylic acid isopropyl ester; 4-[6-(2-Methyl-6-propylamino- pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidine-l -carboxylic acid isopropyl ester; 4-[6-(2-Methyl-6-propylamin

Priority Applications (13)

Applications Claiming Priority (6)

Related Child Applications (2)

Publications (2)

Family

ID=38521309

Family Applications (1)

Country Status (20)

Cited By (68)

Families Citing this family (6)

Citations (191)

Family Cites Families (119)

• 2007
  • 2007-04-09 PE PE2007000419A patent/PE20071221A1/es not_active Application Discontinuation
  • 2007-04-10 DE DE602007011908T patent/DE602007011908D1/de active Active
  • 2007-04-10 AT AT07755258T patent/ATE494888T1/de not_active IP Right Cessation
  • 2007-04-10 EA EA200870425A patent/EA200870425A1/ru unknown
  • 2007-04-10 JP JP2009505453A patent/JP2009533447A/ja active Pending
  • 2007-04-10 AR ARP070101505A patent/AR060409A1/es not_active Application Discontinuation
  • 2007-04-10 EP EP07755258A patent/EP2004157B1/en active Active
  • 2007-04-10 KR KR1020087027464A patent/KR20080108610A/ko not_active Application Discontinuation
  • 2007-04-10 DO DO2007000069A patent/DOP2007000069A/es unknown
  • 2007-04-10 WO PCT/US2007/008926 patent/WO2007120702A2/en active Application Filing
  • 2007-04-10 EP EP10009066A patent/EP2253311A3/en not_active Withdrawn
  • 2007-04-10 US US11/989,038 patent/US7816364B2/en not_active Expired - Fee Related
  • 2007-04-10 AU AU2007238728A patent/AU2007238728A1/en not_active Abandoned
  • 2007-04-10 CA CA2650399A patent/CA2650399C/en not_active Expired - Fee Related
  • 2007-04-10 ME MEP-274/08A patent/MEP27408A/xx unknown
  • 2007-04-10 TW TW096112545A patent/TW200811178A/zh unknown
  • 2007-04-10 MX MX2008013135A patent/MX2008013135A/es not_active Application Discontinuation
  • 2007-04-11 PA PA20078722801A patent/PA8722801A1/es unknown
  • 2007-04-11 UY UY30277A patent/UY30277A1/es unknown
• 2008
  • 2008-09-18 IL IL194214A patent/IL194214A0/en unknown
  • 2008-11-10 NO NO20084748A patent/NO20084748L/no not_active Application Discontinuation
• 2010
  • 2010-04-01 US US12/752,671 patent/US8101626B2/en not_active Expired - Fee Related
• 2012
  • 2012-08-27 JP JP2012186623A patent/JP2012229272A/ja active Pending

Patent Citations (195)